Fundraising Fox
Nosis Bio
24 employees on LinkedIn · 4 known investors
Find your way into Nosis Bio
Sign up to find every way you can get introduced to Nosis Bio
- Your email: who you already know at Nosis Bio, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Nosis Bio team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Nosis develops a platform for receptor-targeted delivery of RNA therapeutics to specific cell types, addressing a key bottleneck in RNA drug development. The company aims to reduce the cost and timeline of bringing new RNA medicines to market.
Founders & leadership
Investors · 4
AlleyCorplisted by AlleyCorpNew York · $1M – $5M
How we know: AlleyCorp's portfolio page · the VCSheet dataset · Not right? Tell us
Alley Robotics VenturesreportedCohasset · $500K – $2Mvia Abe Murray · inferred
How we know: the VCSheet dataset · Not right? Tell us
KdT VenturesreportedAustin · $500K – $3M
How we know: the VCSheet dataset · Not right? Tell us
Related companies · 4
bioBIO is the world's largest advocacy association representing biotechnology companies and research institutions across the United States and 30+ other nations. The organization facilitates industry networking through events, conferences, and partnering software while providing cost-savings programs and advocacy services for member companies.
Syneos HealthSyneos Health is a fully integrated biopharmaceutical solutions organization that provides clinical, medical affairs, and commercial services to help pharmaceutical companies accelerate market access and patient outcomes.
Syndeio BiosciencesSyndeio Biosciences is a synapse-focused biotech developing precision neurotherapeutics for neuropsychiatric, mental health, and cognitive disorders such as depression and Alzheimer's. Its proprietary Boost Platform models synapse pharmacology, and its pipeline includes NMDA receptor positive allosteric modulators (zelquistinel and apimostinel) in Phase 2 clinical trials.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies working in the same space as Nosis Bio.
Frequently asked questions
- What does Nosis Bio do?
- Nosis develops a platform for receptor-targeted delivery of RNA therapeutics to specific cell types, addressing a key bottleneck in RNA drug development. The company aims to reduce the cost and timeline of bringing new RNA medicines to market.
- Who founded Nosis Bio?
- Nosis Bio was founded by Seth Myers.
- Who are Nosis Bio's investors?
- Nosis Bio's investors include AlleyCorp, Madrona Venture Group, Alley Robotics Ventures, KdT Ventures.